1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Hyper-CVAD and sequential Blinatumomab in newly diagnosed Ph-negative ALL

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Protocol: Hyper-CVAD and sequential Blinatumomab in newly diagnosed Ph-negative ALL

New Protocol: Hyper-CVAD and sequential Blinatumomab in newly diagnosed Ph-negative ALL
Study:
  • Phase II trial – Newly diagnosed Ph-negative ALL in pts 14-59 yrs (n=39)
  • Hyper-CVAD (with riTUXimab or ofatumumab for CD20 + disease) x 4 cycles followed by 4 cycles of blinatumomab => Maintenance POMP + blinatumomab for cycles 4, 8, and 12
Efficacy:
  • CR: 100%, MRD negativity achieved in 97%
  • OS at 2-yr: 86%. 5 pts (15%) relapsed
Safety:
  • Grade 2-3 cytokine release syndrome in 4 pts.
  • Neurological AEs due to blinatumomab in 14 pts (41%)

Presented at: 62nd ASH Annual Meeting; December 6, 2020. Abstract 464.

Short NC, et al. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

https://ash.confex.com/ash/2020/webprogram/Paper138565.html

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More